News & Updates
Albaron Partners Completes Sale of Beyond Podiatry to CUC Inc. (TSE: 9158)
Jan 16, 2024
New York, NY, January 5, 2024 – Albaron Partners LP (“Albaron”), a middle market private equity firm, is pleased to announce that it has completed the sale of Albaron Podiatry Holdings LLC d/b/a Beyond Podiatry (“Beyond Podiatry”), the Midwest’s leading podiatric medicine practice management company, to CUC Inc. (TSE: 9158), on January 5, 2024. The transaction values the business at $87 million and represents the first acquisition for CUC Inc. (“CUC”) in the U.S. as well as the first private equity exit in U.S. podiatry.
“This is a transformational moment for Beyond Podiatry. We are thrilled for Dr. Stephen Frascone and his fellow physician shareholders, as well as John Moroney, President, and the entire Beyond Podiatry team.” said Alessio Baraldi, Albaron Partners. “CUC is the perfect partner for the platform’s next stage of growth, and we look forward to following Beyond Podiatry’s continued success.”
“I could not have wished for a better first partnership than what we built with Albaron,” said Dr. Frascone, founder and Chief Medical Officer of Beyond Podiatry. “Their strategic direction, operational expertise and vision for growth is unparalleled in the healthcare middle market.”
“We are excited to enter the U.S. podiatry market with Beyond Podiatry,” said Keita Hamaguchi, Founder and CEO of CUC. “Albaron has built a scalable platform that will allow us to rapidly expand throughout the U.S. The team at Beyond Podiatry is a clear market leader and shares our vision for future growth.”
ABOUT BEYOND PODIATRY
With over 200 employees across 30+ locations in the Midwest, Beyond Podiatry treats more than 250,000 patients per year for a variety of lower extremity conditions. Since its founding in 2018, Beyond Podiatry has consistently expanded its footprint through M&A and de novo clinic openings. Beyond Podiatry supports a team of 56 doctors who treat patients across Michigan, Illinois, Ohio, Kentucky, and Indiana. (https://beyond-podiatry.com)
ABOUT CUC
CUC, Inc. (TSE: 9158) is a publicly traded Japanese company with operations in Asia.
CUC began its global expansion in 2019, mainly in Southeast Asia, with its mission of “Creating Hope through Healthcare”. CUC formed CUC America Inc. in July 2023 to undertake market research and facilitate business development in the U.S.
With this acquisition, CUC’s objective is to support the operational capabilities of Beyond Podiatry as a premier practice management platform by utilizing the expertise CUC has gained through its management support for medical institutions in Japan. Going forward, Beyond Podiatry will maintain its operations under the direction of its current management team alongside several directors from CUC.
CUC’s publicly filed announcements regarding the transaction can be found at the following links:
Transaction Signing Press Release
Transaction Signing Investor Presentation
ABOUT ALBARON
Founded in 2017, Albaron is an operationally focused middle market healthcare private equity firm. Albaron’s dedicated team of healthcare investors and operators helps physician founders and management teams scale their businesses and grow leading platforms within their individual specialties. (https://albaronpartners.com)
Cincinnati Foot & Ankle Care Partners with Beyond Podiatry
Nov 17, 2022
Cincinnati, OH and Chicago, IL, November 17, 2022 – Cincinnati Foot & Ankle Care (“CFAC”), one of the largest independent podiatry groups in Ohio, has partnered with Beyond Podiatry, one of the largest podiatry practice management organizations in the Midwest and a portfolio company of Albaron Partners, LP. Founded in 1998, CFAC is a leading podiatric medical practice of nineteen (19) experienced foot & ankle surgeons with several clinics in the Greater Cincinnati area. “We are excited to be part of the Beyond Podiatry family”, said Nickolas A. Minnie, DPM, managing partner of CFAC, “we believe that the future growth and success of CFAC with Beyond Podiatry will be transformative in our industry while providing optimal patient experiences and efficiencies in our quality of care.” For John Moroney, Beyond Podiatry’s President, this marked another milestone in the company’s strategic partnership with best-in-class podiatry practices, noting “we are extremely excited about this transformational partnership with CFAC as it solidifies our position as the leading podiatry platform in the Midwest.”
ABOUT CINCINNATI FOOT & ANKLE CARE
Founded in 1998 and based in Cincinnati, OH, Cincinnati Foot & Ankle Care is Greater Cincinnati’s leading podiatry practice of foot & ankle surgeons committed to providing the highest quality of care and treatment for all types of foot and ankle injuries and conditions for patients of all ages. For more information, please visit: www.cfac.net
ABOUT BEYOND PODIATRY
Beyond Podiatry provides patients with the most advanced and comprehensive foot and ankle care treatment options to meet their personalized needs. As a team, they combine the skills of some of the premier podiatric medicine experts in the country and seasoned operating professionals with experience in running large healthcare organizations. For more information, please visit: www.beyond-podiatry.com
ABOUT ALBARON
Albaron is a U.S. private equity firm that invests in and helps accelerate the growth of physician practice groups and microcap healthcare companies. The firm’s goal is to build best-in-class healthcare services platforms that maximize outcomes for all constituents – patients, providers, payors and investors. Albaron’s team is comprised of a seasoned cohort of operating experts and investment professionals who are uniquely qualified to realize significant value through strategic insights, operating support and accretive acquisitions. The team works collaboratively with partnering management teams and leverages its network of industry experts to augment its capabilities. For more information, please visit: www.albaronpartners.com
FORWARD-LOOKING STATEMENTS
This communication expressly or implicitly contains certain forward-looking statements that involve risks and uncertainties, including statements regarding expectations about the business of Beyond Podiatry. If any of these risks or uncertainties materialize, or if such assumptions prove incorrect, financial or operational results of Albaron Partners and its affiliates, including Beyond Podiatry, could differ materially from the results expressed or implied by these forward-looking statements. All forward-looking statements in this communication are based on information available to Albaron Partners and its affiliates, including Beyond Podiatry, as of the date of this communication, and none of Albaron Partners or any of its affiliates, including Beyond Podiatry, assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made, except as required by applicable law.
New Republic Partners Makes Strategic Investment in Innovation Fertility
Nov 3, 2022
New York, NY, November 3, 2022 – Innovation Fertility, a network of leading IVF clinics and laboratories that provide IVF services and infertility care across the country, announced today an investment by New Republic Partners, an investment management and wealth advisory firm. The firm joined with Albaron Partners, LP (“Albaron”) the current owner of Innovation Fertility, to provide capital to support the long-term growth strategy of the healthcare platform.
The $8B U.S. fertility market includes in-vitro fertilization, genetic testing, reproductive tissue storage and donor services. This market continues to benefit from long-term demand drivers and strong growth rates.
Sam Bowles, managing director at New Republic Partners, says, “Albaron Partner’s deep experience in this industry coupled with strong market expansion opportunities makes this an attractive investment opportunity.”
Innovation Fertility is led by Dwight Ryan, chief executive officer, a seasoned healthcare executive with extensive years of financial, accounting and operations experience within the infertility industry, and Dr. Kathleen Miller, Chief Science Officer, a world-known leader for research advances in the field of blastocyst culture and pre-implantation genetics as well as a leading expert in laboratory management, quality improvement programs, and single embryo transfer.
Innovation Fertility provides patients with innovative, cutting-edge fertility treatment options to meet their unique family planning goals. As a team, they combine premier reproductive endocrinologists with laboratory operations, resulting in exceptional medical care and an unparalleled patient experience.
The organization’s growth strategies include plans to invest in practices across the U.S. to enable practice growth and profitability. Current investment holdings include practices in North Carolina, Ohio, Michigan and Montana.
ABOUT INNOVATION FERTILITY
Innovation Fertility provides patients with innovative, cutting-edge fertility treatment options to meet their unique family planning goals. As a team, they combine premier reproductive endocrinologists with laboratory operations, resulting in exceptional medical care and an unparalleled patient experience. Learn more at http://www.iffertility.com.
ABOUT NEW REPUBLIC PARTNERS
New Republic Partners is an innovative investment management and wealth advisory firm serving successful individuals and families, endowments and foundations. Our clients benefit from access to investment opportunities usually reserved for large institutional investors, bespoke asset-class-specific fund offerings, customized portfolios, complex planning, and the expertise and experience of a successful and seasoned investment management, wealth advisory and credit solutions team. The firm is headquartered in Charlotte, North Carolina. More information is available at http://www.newrepublicpartners.com
ABOUT ALBARON
Albaron is a U.S. private equity firm that invests in and helps accelerate the growth of physician practice groups and microcap healthcare companies. The firm’s goal is to build best-in-class healthcare services platforms that maximize outcomes for all constituents – patients, providers, payors and investors. Albaron’s team is comprised of a seasoned cohort of operating experts and investment professionals who are uniquely qualified to realize significant value through strategic insights, operating support and accretive acquisitions. The team works collaboratively with management teams and leverages its network of industry experts to augment its capabilities. For more information, visit http://www.albaronpartners.com.
FORWARD-LOOKING STATEMENTS
This communication expressly or implicitly contains certain forward-looking statements that involve risks and uncertainties. If any of these risks or uncertainties materialize, or assumptions by New Republic Partners, Albaron Partners or Innovation Fertility prove incorrect, results could differ materially from the results expressed or implied by these forward-looking statements. All forward-looking statements in this communication are based on information available to New Republic Partners, Albaron Partners and Innovation Fertility as of the date of this communication, and New Republic Partners, Albaron Partners and Innovation Fertility do not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Albaron Partners Formally Announces Launch of Innovation Fertility Ahead of ASRM
Oct 1, 2022
New York, NY, and Anaheim, CA, October 1, 2022 – Albaron Partners, LP (“Albaron”), a U.S. private equity firm focused on acquiring majority stakes of companies in the specialty healthcare services sector, today announced the formal launch of Innovation Fertility, a network of leading IVF clinics and laboratories, ahead of the American Society for Reproductive Medicine (“ASRM”) Scientific Congress & Expo. in Anaheim, CA, October 22-26, 2022. This is the premier event for reproductive medicine, drawing top experts from around the world.
Innovation Fertility is led by a dynamic and seasoned team of reproductive health and business professionals with years of experience in building successful fertility practices. Their decades of expertise spans laboratory design, technology implementation, strategic planning, and operations support.
“We have been working toward this pivotal moment for some time,” says Dwight P. Ryan, CEO of Innovation Fertility. “Our mission is to leverage our collective experience to empower our partner practices and help deliver better outcomes for more families. But we want these practices to retain what makes them unique and trusted by their patient population.”
The forward-thinking theme of the ASRM 2022 meeting — “Genes, Gametes, and Genetics: What Will the Future Hold?” — is in-step with the organization’s new core messaging, which asks practices to imagine “What IF?” Innovation Fertility is on the other side of that question, offering greater efficacy, more support, and better technology. In a time when much value is often placed on the disruptive era of fertility care, Innovation places greater emphasis on following the science and embracing innovative, evidence-based solutions.
“For years, the leadership team has brought the best technology and laboratory practices to fertility clinics,” says Dr. Kathleen Miller, Chief Science Officer at Innovation Fertility. “We are known for being data-driven, science-first insiders. It’s exciting to have a brand that elevates our work and commitment to our practice partners, but we’re also proud to be more than a brand. Years of research, dedication, and big thinking have gotten us here.”
Though ASRM will mark the organization’s formal debut, Innovation Fertility has already been working with fertility practices across the country, giving them the autonomy to run day-to-day operations as they see fit, while bolstering them with the additional support they need to streamline internal operations and scale accordingly.
Learn more about Innovation Fertility at ASRM, October 22-26, 2022 at booth 1502.
ABOUT ALBARON
Albaron is a U.S. private equity firm that invests in and helps accelerate the growth of physician practice groups and microcap healthcare companies. The firm’s goal is to build best-in-class healthcare services platforms that maximize outcomes for all constituents – patients, providers, payors and investors. Albaron’s team is comprised of a seasoned cohort of operating experts and investment professionals who are uniquely qualified to realize significant value through strategic insights, operating support and accretive acquisitions. The team works collaboratively with partnering management teams and leverages its network of industry experts to augment its capabilities. For more information, visit: www.albaronpartners.com
ABOUT INNOVATION FERTILITY
Innovation Fertility provides patients with innovative, cutting-edge fertility treatment options to meet their unique family planning goals. As a team, they combine some of the premier reproductive endocrinologists of the world with the most experienced laboratory managers and operators in the space, resulting in exceptional medical care and an unparalleled patient experience. For more information, visit: www.iffertility.com
FORWARD-LOOKING STATEMENTS
This communication expressly or implicitly contains certain forward-looking statements that involve risks and uncertainties, including statements regarding expectations for Innovation Fertility following its acquisition by Albaron Partners. If any of these risks or uncertainties materialize, or if any of Innovation Fertility’s or Albaron Partners’ assumptions prove incorrect, Innovation Fertility’s results could differ materially from the results expressed or implied by these forward-looking statements. All forward-looking statements in this communication are based on information available to Innovation Fertility and Albaron Partners as of the date of this communication, and Innovation Fertility and Albaron Partners do not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Albaron Partners Acquires SpringCreek Fertility
Mar 2, 2022
New York, NY, and Columbus, OH, March 2, 2022 – SpringCreek Fertility, an Ohio-based, regional leader in reproductive endocrinology, and Albaron Partners, LP (“Albaron”), a U.S. private equity firm focused on acquiring majority stakes of companies in the specialty healthcare services sector, today announced that SpringCreek Fertility has been acquired by affiliates of Albaron. SpringCreek Fertility will become part of Innovation Fertility, Albaron’s reproductive endocrinology platform. The financial terms of the transaction were not disclosed. Company Founder and Chief Medical Officer, Dr. Jeremy Groll, has retained a minority ownership stake in SpringCreek Fertility.
ABOUT SPRINGCREEK FERTILITY
Based in Columbus, OH, SpringCreek Fertility is a state-of-the-art fertility center offering comprehensive reproductive health care treatment options, including in vitro fertilization, egg donation, genetic testing, intrauterine insemination, egg freezing and gestational carrying. Founded in 2014 by Dr. Jeremy Groll, the award-winning term of fertility specialists at SpringCreek Fertility complete around 600 IVF cycles each year. For more information, visit: www.springcreekfertility.com
ABOUT INNOVATION FERTILITY
Innovation Fertility provides patients with innovative, cutting-edge fertility treatment options to meet their unique family planning goals. As a team, they combine some of the premier reproductive endocrinologists of the world with the most experienced laboratory managers and operators in the space, resulting in exceptional medical care and an unparalleled patient experience. For more information, visit: www.iffertility.com
ABOUT ALBARON
Albaron is a U.S. private equity firm that invests in and helps accelerate the growth of physician practice groups and microcap healthcare companies. The firm’s goal is to build best-in-class healthcare services platforms that maximize outcomes for all constituents – patients, providers, payors and investors. Albaron’s team is comprised of a seasoned cohort of operating experts and investment professionals who are uniquely qualified to realize significant value through strategic insights, operating support and accretive acquisitions. The team works collaboratively with partnering management teams and leverages its network of industry experts to augment its capabilities. For more information, visit: www.albaronpartners.com
FORWARD-LOOKING STATEMENTS
This communication expressly or implicitly contains certain forward-looking statements that involve risks and uncertainties, including statements regarding expectations for SpringCreek Fertility following its acquisition by Albaron. If any of these risks or uncertainties materialize, or if any of SpringCreek Fertility’s or Albaron’s assumptions prove incorrect, SpringCreek Fertility’s results could differ materially from the results expressed or implied by these forward-looking statements. All forward-looking statements in this communication are based on information available to SpringCreek Fertility and Albaron as of the date of this communication, and SpringCreek Fertility and Albaron do not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Lincoln Richards Joins Albaron Partners as Vice President
Dec 1, 2021
New York, NY, December 1, 2021 – Albaron Partners, LP (“Albaron”), a U.S. private equity firm focused on acquiring majority stakes of companies in the specialty healthcare services sector, today announced that Lincoln Richards has joined the investment team as a Vice President.
Richards will be responsible for evaluating potential acquisition targets, conducting due diligence, and overseeing portfolio company operations. He joins Albaron from private equity firm TZP Group, where he was an Associate. Prior to TZP Group, he spent two years on the Sellside M&A team at McColl Partners (acquired by Deloitte). Richards earned his BS degree from Duke University.
“We are thrilled to welcome Lincoln to the firm,” said Damian Dalla-Longa, Partner at Albaron.
“As a recognized emerging private equity leader, he knows the industry and understands why Albaron is a special place to work. We believe that the firm’s continued success is a direct result of our exceptional talent and distinctive culture and are excited to see what we will accomplish together with Lincoln as part of our team.”
ABOUT ALBARON
Albaron is a U.S. private equity firm that invests in and helps accelerate the growth of physician practice groups and microcap healthcare companies. The firm’s goal is to build best-in-class healthcare services platforms that maximize outcomes for all constituents – patients, providers, payors and investors. Albaron’s team is comprised of a seasoned cohort of operating experts and investment professionals who are uniquely qualified to realize significant value through strategic insights, operating support and accretive acquisitions. The team works collaboratively with partnering management teams and leverages its network of industry experts to augment its capabilities. For more information, visit: www.albaronpartners.com
FORWARD-LOOKING STATEMENTS
This communication expressly or implicitly contains certain forward-looking statements that involve risks and uncertainties, including statements regarding expectations for Albaron following its appointment of Lincoln Richards as Vice President. If any of these risks or uncertainties materialize, or if any of Albaron’s assumptions prove incorrect, Albaron’s results could differ materially from the results expressed or implied by these forward-looking statements. All forward-looking statements in this communication are based on information available to Albaron as of the date of this communication, and Albaron does not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
First Step Foot Care Acquired by Albaron Partners
Sep 30, 2021
Chicago, IL and New York, NY, September 30, 2021 – First Step Foot Care, an Illinois-based, regional leader in comprehensive foot and ankle care, and Albaron Partners, LP (“Albaron”), a U.S. private equity firm focused on acquiring majority stakes of companies in the specialty healthcare services sector, today announced that First Step Foot Care has been acquired by affiliates of Albaron Partners. First Step Foot Care will become part of Beyond Podiatry, Albaron’s podiatry management services organization. The financial terms of the transaction were not disclosed. Practice founder and chief medical officer,
Dr. James Flood, has retained a minority ownership stake in First Step Foot Care.
ABOUT FIRST STEP FOOT CARE
Based in Chicago, IL, First Step Foot Care is a regional leader in providing a comprehensive service of care for foot and ankle conditions, including sports and trauma injuries, arthritis, metatarsalgia, diabetic care, and reconstructive foot surgery. Founded in 1991 by Dr. Flood, the practice sees 25,000 patients each year in its three clinics across the Chicago metropolitan area. For more information, visit: www.firststepfootcare.com
ABOUT BEYOND PODIATRY
Beyond Podiatry provides patients with the most advanced and comprehensive foot and ankle care treatment options to meet their personalized needs. As a team, they combine the skills of some of the premier podiatric medicine experts in the country and seasoned operating professionals with experience in running large healthcare organizations. For more information, visit: www.beyond-podiatry.com
ABOUT ALBARON
Albaron is a U.S. private equity firm that invests in and helps accelerate the growth of physician practice groups and microcap healthcare companies. The firm’s goal is to build best-in-class healthcare services platforms that maximize outcomes for all constituents – patients, providers, payors and investors. Albaron’s team is comprised of a seasoned cohort of operating experts and investment professionals who are uniquely qualified to realize significant value through strategic insights, operating support and accretive acquisitions. The team works collaboratively with partnering management teams and leverages its network of industry experts to augment its capabilities. For more information, visit: www.albaronpartners.com
FORWARD-LOOKING STATEMENTS
This communication expressly or implicitly contains certain forward-looking statements that involve risks and uncertainties, including statements regarding expectations for First Step Foot Care following its acquisition by Albaron. If any of these risks or uncertainties materialize, or if any of First Step Foot Care’s or Albaron’s assumptions prove incorrect, First Step Foot Care’s results could differ materially from the results expressed or implied by these forward-looking statements. All forward-looking statements in this communication are based on information available to First Step Foot Care and Albaron as of the date of this communication, and First Step Foot Care and Albaron do not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Commonwealth Foot and Ankle Center Acquired by Albaron Partners
Jul 26, 2021
New York, NY, and Louisville, KY, July 26, 2021 – Commonwealth Foot and Ankle Center, a Kentucky-based, regional leader in comprehensive foot and ankle care, and Albaron Partners, LP (“Albaron”), a U.S. private equity firm focused on acquiring majority stakes of companies in the specialty healthcare services sector, today announced Commonwealth Foot and Ankle Center has been acquired by affiliates of Albaron. Commonwealth Foot and Ankle Center will become part of Beyond Podiatry, Albaron’s podiatry management services organization. The financial terms of the transaction were not disclosed.
McGuireWoods, LLP served as legal advisor to Albaron.
ABOUT COMMONWEALTH FOOT AND ANKLE CENTER
Based in Louisville, KY, Commonwealth Foot and Ankle Center is a regional leader in specialized diabetic foot care, reconstructive foot and ankle surgery, foot wound care, skin and nail procedures and foot and ankle fractures. Founded in 1982, the Company sees over 10,000 patients each year in its Louisville office. For more information, visit: www.commonwealthfootandankle.com
ABOUT BEYOND PODIATRY
Beyond Podiatry provides patients with the most advanced and comprehensive foot and ankle care treatment options to meet their personalized needs. As a team, they combine the skills of some of the premier podiatric medicine experts in the country and seasoned operating professionals with experience in running large healthcare organizations. For more information, visit: www.beyond-podiatry.com
ABOUT ALBARON
Albaron is a U.S. private equity firm that invests in and helps accelerate the growth of physician practice groups and microcap healthcare companies. The firm’s goal is to build best-in-class healthcare services platforms that maximize outcomes for all constituents – patients, providers, payors and investors. Albaron’s team is comprised of a seasoned cohort of operating experts and investment professionals who are uniquely qualified to realize significant value through strategic insights, operating support and accretive acquisitions. The team works collaboratively with partnering management teams and leverages its network of industry experts to augment its capabilities.
FORWARD-LOOKING STATEMENTS
This communication expressly or implicitly contains certain forward-looking statements that involve risks and uncertainties, including statements regarding expectations for Commonwealth Foot and Ankle Center following its acquisition by Albaron. If any of these risks or uncertainties materialize, or if any of Commonwealth Foot and Ankle Center’s or Albaron’s assumptions prove incorrect, Commonwealth Foot and Ankle Center’s results could differ materially from the results expressed or implied by these forward-looking statements. All forward-looking statements in this communication are based on information available to Commonwealth Foot and Ankle Center and Albaron as of the date of this communication, and Commonwealth Foot and Ankle Center and Albaron do not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Albaron Partners Acquires RMA of Michigan
July 18, 2021
New York, NY, and Detroit, MI, July 18, 2021 – RMA of Michigan, a Michigan-based, regional leader in advanced fertility care, and Albaron Partners, LP (“Albaron”), a U.S. private equity firm focused on acquiring majority stakes of companies in the specialty healthcare services sector, today announced that RMA of Michigan has been acquired by affiliates of Albaron. RMA of Michigan will become part of Innovation Fertility, Albaron’s reproductive endocrinology platform. The financial terms of the transaction were not disclosed. Company founder and Chief Medical Officer, Dr. Brad Miller, has retained a minority ownership stake in RMA of Michigan.
Reproductive endocrinology is among the fastest-growing medical specialties in the country. Demand for advanced fertility care will continue to rise as couples are deciding to have children later in life and the prevalence of male infertility, driven by environmental and lifestyle factors, increases. Further trends favoring industry demand are a growing percentage of same-sex couples desiring children and an increasing number of employers offering benefits for IVF and genetic testing services.
“We welcome Dr. Brad Miller and the entire RMA of Michigan team to the Innovation Fertility family. The acquisition brings together two organizations with an unwavering commitment to patient experience and outcomes,” said Albaron Founder and Partner Alessio Baraldi. “The mission of RMA of Michigan has always been to provide personalized fertility care with the highest chances of success. We are thrilled to partner with Albaron and are excited about the operating capabilities and capital resources they provide to complement the strength of our exceptional clinical team,” said Dr. Miller. RMA of Michigan’s commitment to providing a first-class patient experience remains unchanged, and management expects that under the leadership of Innovation Fertility, they will have the flexibility and expertise to focus on what matters most – helping patients build their families.
ABOUT RMA OF MICHIGAN
Based in Detroit, MI, RMA of Michigan is one of the leading fertility clinics in the Midwest. Founded in 2006 by Dr. Bradley Miller, the Company’s three physicians complete around 800 IVF cycles each year. For more information, visit: www.rmami.com
ABOUT INNOVATION FERTILITY
Innovation Fertility provides patients with innovative, cutting-edge fertility treatment options to meet their unique family planning goals. As a team, they combine some of the premier reproductive endocrinologists of the world with the most experienced laboratory managers and operators in the space, resulting in exceptional medical care and an unparalleled patient experience. For more information, visit: www.iffertility.com
ABOUT ALBARON
Albaron is a U.S. private equity firm that invests in and helps accelerate the growth of physician practice groups and microcap healthcare companies. The firm’s goal is to build best-in-class healthcare services platforms that maximize outcomes for all constituents – patients, providers, payors and investors. Albaron’s team is comprised of a seasoned cohort of operating experts and investment professionals who are uniquely qualified to realize significant value through strategic insights, operating support and accretive acquisitions. The team works collaboratively with partnering management teams and leverages its network of industry experts to augment its capabilities. For more information, visit: www.albaronpartners.com
FORWARD-LOOKING STATEMENTS
This communication expressly or implicitly contains certain forward-looking statements that involve risks and uncertainties, including statements regarding expectations for RMA of Michigan following its acquisition by Albaron. If any of these risks or uncertainties materialize, or if any of RMA of Michigan’s or Albaron’s assumptions prove incorrect, RMA of Michigan’s results could differ materially from the results expressed or implied by these forward-looking statements. All forward-looking statements in this communication are based on information available to RMA of Michigan and Albaron as of the date of this communication, and RMA of Michigan and Albaron do not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Albaron Partners Announces New Fertility Clinic in Charlotte, Creating a National Reproductive Endocrinology Platform
Oct 20, 2020
New York, NY, and Charlotte, NC, October 4, 2020 – Albaron Partners, LP (“Albaron”), a U.S. private equity firm focused on acquiring majority stakes of companies in the specialty healthcare services sector, today announced that it has partnered with a Charlotte-based reproductive endocrinologist to offer advanced fertility treatments under the name of Reproductive Specialists of the Carolinas. The new clinic will be led by Dr. Matrika Johnson, a dual board-certified OB/GYN and reproductive endocrinologist recently recognized as one of Charlotte’s “Top Doctors” by Charlotte Magazine. The investment in Reproductive Specialists of the Carolinas anchors Innovation Fertility, a management services organization specializing in reproductive endocrinology in the Charlotte market. The financial terms of the deal were not disclosed.
Reproductive endocrinology is among the fastest-growing medical specialties. Demand for advanced fertility care will continue to rise as couples are deciding to have children later in life and the prevalence of male infertility, driven by environmental and lifestyle factors, increases. Further trends favoring industry demand are a growing percentage of same-sex couples desiring children and an increasing number of employers offering benefits for IVF and genetic testing services.
“We are thrilled to have Dr. Johnson leading our Charlotte office,” explained Damian Dalla-Longa, Founder and Partner of Albaron. He continued, “Dr. Johnson is incredibly passionate about helping people build families. Her extensive knowledge and her intimate, personalized approach to patient care are completely aligned with our goal of providing the most advanced treatment options and the best patient care. Together, we look forward to leading the way in innovative and patient-centric fertility care in North Carolina.”
ABOUT DR. MATRIKA JOHNSON
Matrika D. Johnson, M.D., is board-certified in Obstetrics and Gynecology as well as Reproductive Endocrinology and Infertility. Since 2020, Dr. Johnson has appeared in Charlotte Magazine’s list of the Top Doctors in Charlotte for reproductive endocrinology and infertility.
ABOUT INNOVATION FERTILITY
Innovation Fertility provides patients with innovative, cutting-edge fertility treatment options to meet their unique family planning goals. As a team, they combine some of the premier reproductive endocrinologists of the world with the most experienced laboratory managers and operators in the space, resulting in exceptional medical care and an unparalleled patient experience. For more information, visit: www.iffertility.com
ABOUT ALBARON
Albaron is a U.S. private equity firm that invests in and helps accelerate the growth of physician practice groups and microcap healthcare companies. The firm’s goal is to build best-in-class healthcare services platforms that maximize outcomes for all constituents – patients, providers, payors and investors. Albaron’s team is comprised of a seasoned cohort of operating experts and investment professionals who are uniquely qualified to realize significant value through strategic insights, operating support and accretive acquisitions. The team works collaboratively with partnering management teams and leverages its network of industry experts to augment its capabilities. For more information, visit: www.albaronpartners.com
FORWARD-LOOKING STATEMENTS
This communication expressly or implicitly contains certain forward-looking statements that involve risks and uncertainties, including statements regarding expectations for Reproductive Specialists of the Carolinas following its acquisition by Albaron Partners. If any of these risks or uncertainties materialize, or if any of Reproductive Specialists of the Carolinas’ or Albaron Partners’ assumptions prove incorrect, Reproductive Specialists of the Carolinas’ results could differ materially from the results expressed or implied by these forward-looking statements. All forward-looking statements in this communication are based on information available to Reproductive Specialists of the Carolinas and Albaron Partners as of the date of this communication, and Reproductive Specialists of the Carolinas and Albaron Partners do not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Debo Adesina Joins Albaron Partners as Partner and Chief Legal Officer
Feb 1, 2020
New York, NY, and Dallas, TX, February 1, 2020 – Albaron Partners, LP (“Albaron”), a U.S. private equity firm focused on acquiring majority stakes of companies in the specialty healthcare services sector, today announced an appointment within its senior leadership team.
Debo Adesina joins Albaron as Partner and Chief Legal Officer. Previously, Adesina served as a Partner at McGuireWoods LLP, where he was a leader in the firm’s middle market private equity and M&A practices. He has extensive healthcare and life sciences transaction experience and represented Albaron on a variety of transactions and mandates since 2018. In his new role, Adesina will lead Albaron’s Legal & Compliance department and will play an important role in growing portfolio companies as an active board member.
“Over the years, Debo has been a tremendous partner to Albaron and we are thrilled to welcome him to our team and to continue working together,” said Alessio Baraldi, Founder and Partner of Albaron. He added, “Debo is an excellent attorney whose entrepreneurial spirit, innovative thinking, legal acumen and depth of insight around a wide range of healthcare sectors will be a significant asset to our organization. His appointment reflects the deep bench of talent Albaron was able to recruit and accelerates our journey towards building an agile, best-in-class investment team.”
ABOUT ALBARON
Albaron is a U.S. private equity firm that invests in and helps accelerate the growth of physician practice groups and microcap healthcare companies. The firm’s goal is to build best-in-class healthcare services platforms that maximize outcomes for all constituents – patients, providers, payors and investors. Albaron’s team is comprised of a seasoned cohort of operating experts and investment professionals who are uniquely qualified to realize significant value through strategic insights, operating support and accretive acquisitions. The team works collaboratively with partnering management teams and leverages its network of industry experts to augment its capabilities. For more information, visit: www.albaronpartners.com
FORWARD-LOOKING STATEMENTS
This communication expressly or implicitly contains certain forward-looking statements that involve risks and uncertainties, including statements regarding expectations for Albaron following its appointment of Debo Adesina as a Partner. If any of these risks or uncertainties materialize, or if any of Albaron’s assumptions prove incorrect, Albaron’s results could differ materially from the results expressed or implied by these forward-looking statements. All forward-looking statements in this communication are based on information available to Albaron as of the date of this communication, and Albaron does not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Foot and Ankle Associates Aquired By Albaron Partners
Nov 14, 2019
Chicago, IL and New York, NY, November 14, 2019 – Foot & Ankle Associates, an Illinois-based, regional leader in comprehensive foot and ankle care, and Albaron Partners, LP (“Albaron”), a U.S. private equity firm focused on acquiring majority stakes of companies in the specialty healthcare services sector, today announced that Foot & Ankle Associates has been acquired by affiliates of Albaron. Foot & Ankle Associates will become part of Beyond Podiatry, the first private equity backed podiatry management services organization. The financial terms of the transaction were not disclosed. Practice founder and chief medical officer, Dr. John Grady, has retained a minority ownership stake in Foot & Ankle Associates
ABOUT FOOT & ANKLE ASSOCIATES
Based in Chicago, IL, Foot & Ankle Associates is a regional leader in providing a breadth of foot and ankle treatments, from routine care to advanced surgical reconstruction and trauma: sports and trauma injuries, emergency care, corrective foot and ankle surgery, diabetic foot care, ulcer and wound management, pediatric foot and ankle care, ankle replacement surgery. Founded in 1999 by Dr. Grady, the practice sees 35,000 patients each year in its three clinics across the Chicago metropolitan area. For more information, visit: www.footandankleinstitute.com
ABOUT BEYOND PODIATRY
Beyond Podiatry provides patients with the most advanced and comprehensive foot and ankle care treatment options to meet their personalized needs. As a team, they combine the skills of some of the premier podiatric medicine experts in the country and seasoned operating professionals with experience in running large healthcare organizations. For more information, visit: www.beyond-podiatry.com
ABOUT ALBARON
Albaron is a U.S. private equity firm that invests in and helps accelerate the growth of physician practice groups and microcap healthcare companies. The firm’s goal is to build best-in-class healthcare services platforms that maximize outcomes for all constituents – patients, providers, payors and investors. Albaron’s team is comprised of a seasoned cohort of operating experts and investment professionals who are uniquely qualified to realize significant value through strategic insights, operating support and accretive acquisitions. The team works collaboratively with partnering management teams and leverages its network of industry experts to augment its capabilities. For more information, visit: www.albaronpartners.com
FORWARD-LOOKING STATEMENTS
This communication expressly or implicitly contains certain forward-looking statements that involve risks and uncertainties, including statements regarding expectations for Foot & Ankle Associates following its acquisition by Albaron. If any of these risks or uncertainties materialize, or if any of Foot & Ankle Associates’ or Albaron’s assumptions prove incorrect, Foot & Ankle Associates’ results could differ materially from the results expressed or implied by these forward-looking statements. All forward-looking statements in this communication are based on information available to Foot & Ankle Associates and Albaron as of the date of this communication, and Foot & Ankle Associates and Albaron do not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Albaron Partners Acquires Great Lakes Foot & Ankle Institute, Creating a Midwest Focused Podiatry Platform
Jan 8, 2019
New York, NY, and Detroit, MI, January 8, 2019 – Great Lakes Foot & Ankle Institute, a Michigan-based, regional leader in comprehensive foot and ankle care, and Albaron Partners, LP (“Albaron”), a U.S. private equity firm focused on acquiring majority stakes of companies in the specialty healthcare services sector, today announced that Great Lakes Foot & Ankle Institute has been acquired by affiliates of Albaron. The investment in Great Lakes Foot & Ankle Institute anchors Beyond Podiatry, the first private equity backed podiatry management services organization. Financial terms of the transaction were not disclosed. Founder and Chief Medical Officer, Dr. Stephen Frascone, has retained a minority ownership stake in Great Lakes Foot & Ankle Institute.
With the completion of the transaction, Great Lakes Foot & Ankle Institute is now positioned to capitalize on the many benefits this partnership is expected to bring to the Company and its stakeholders. “The Great Lakes Foot & Ankle Institute team looks forward to leveraging Albaron’s operating capabilities, capital resources and healthcare expertise to further expand its geographic reach and service offerings as part of the Beyond Podiatry network,” explained Dr. Frascone. The company’s commitment to providing a first-class patient experience remains unchanged, and it expects that together with Albaron, it will have the flexibility and expertise to focus on what matters most – patient care, investing in continued innovation and developing new ancillary service lines to deliver increased value for patients and growth for Great Lakes Foot & Ankle Institute.
“The completion of this transaction marks the beginning of an exciting new chapter for Great Lakes Foot & Ankle Institute”, said Dr. Frascone. He continued, “I am proud of the position we have established in the Michigan market over the last several years. Our success is a testament to the team’s hard work and dedication to providing an outstanding patient experience. There are significant opportunities ahead for Great Lakes Foot & Ankle Institute as part of a dynamic and growing platform, and I look forward to watching the success of Beyond Podiatry for years to come.”
“We have tracked the significant opportunities in the podiatry market for several years and are excited to partner with Dr. Frascone and the talented team at Great Lakes Foot & Ankle Institute to continue building the company’s position to a leader in the U.S. podiatry market,” said Alessio Baraldi, Founder and Partner of Albaron. Baraldi added, “Dr. Frascone’s superior reputation and proven leadership capabilities make him the ideal partner for Beyond Podiatry. He has built a regional center of excellence in podiatry with a strong culture that is well positioned for this next chapter of exciting growth”.
ABOUT GREAT LAKES FOOT & ANKLE INSTITUTE
Based in Detroit, MI, Great Lakes Foot & Ankle Institute is a regional leader in treating a breadth of acute and chronic foot and ankle conditions including foot and ankle trauma, diabetic wounds, fractures, infections, sports injuries, plantar fasciitis, bunions, arthritis, gout, tendon ruptures, ingrown toenails, sprained ankles, toenail fungus, athlete’s foot, and more. Founded in 1978, the practice sees more than 45,000 patients each year in its five clinics across the Detroit metropolitan area. For more information, visit: www.greatlakesfootandankle.com
ABOUT ALBARON
Albaron is a U.S. private equity firm that invests in and helps accelerate the growth of physician practice groups and microcap healthcare companies. The firm’s goal is to build best-in-class healthcare services platforms that maximize outcomes for all constituents – patients, providers, payors and investors. Albaron’s team is comprised of a seasoned cohort of operating experts and investment professionals who are uniquely qualified to realize significant value through strategic insights, operating support and accretive acquisitions. The team works collaboratively with partnering management teams and leverages its network of industry experts to augment its capabilities. For more information, visit: www.albaronpartners.com
FORWARD-LOOKING STATEMENTS
This communication expressly or implicitly contains certain forward-looking statements that involve risks and uncertainties, including statements regarding expectations for Great Lakes Foot and Ankle Institute following its acquisition by Albaron. If any of these risks or uncertainties materialize, or if any of Great Lakes Foot and Ankle Institute’s or Albaron’s assumptions prove incorrect, Great Lakes Foot and Ankle Institute’s results could differ materially from the results expressed or implied by these forward-looking statements. All forward-looking statements in this communication are based on information available to Great Lakes Foot and Ankle Institute and Albaron as of the date of this communication, and Great Lakes Foot and Ankle Institute and Albaron do not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.